Climate Change Data

Centrient Pharmaceuticals

Climate Impact & Sustainability Data (2018-01 to 2019-12, 2020-2021, 2022-2023, 2023)

Reporting Period: 2018-01 to 2019-12

Environmental Metrics

Total Carbon Emissions:328,742 tCO2e/year (Scope 1 & 2)
Total Energy Consumption:4,461 TJ/year
Water Consumption:3,638,000 m3/year

ESG Focus Areas

  • Antimicrobial Resistance (AMR)
  • Water and environment
  • Improving access
  • Science and Innovation
  • Climate and energy
  • Responsible procurement

Environmental Achievements

  • Hit the vast majority of environmental targets for 2020
  • Semi-synthetic penicillin (SSP) API product range meets PNEC discharge targets set by the AMR Industry Alliance two years ahead of schedule
  • Received EcoVadis Gold sustainability rating (top 4% of companies in the “Manufacture of basic pharmaceutical products and pharmaceutical preparations” industry)
  • Reduced carbon footprint by up to 65% compared with the traditional chemical process for PureActives®

Social Achievements

  • Expanded CSR approach in India and Mexico with positive impact on health and education
  • Appropriate Antibiotic Use project in China rolled out across 70 hospitals
  • Launched several fitness-driven initiatives for employees (health check-up camps, fitness bikes, fitness dance sessions, yoga day, Happy Garden initiative)
  • Launched the TOR scheme for older employees in the Netherlands to improve work-life balance
  • Launched Centrient Young Professionals Network

Governance Achievements

  • Introduced PSCI principles and PSCI audit programme in own operations and full supply chain
  • First AMR supplier assessment survey done
  • Developed a Sustainability Assessment Tool (SAT)
  • Implemented Sustainability Assessment through the Self-Assessment Questionnaire (SAQ)
  • Adopted Guidelines for Disciplinary Sanctions

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Achieve 43% overall energy efficiency improvement by 2020
  • Realise a 49% CO2 efficiency improvement by 2020
  • Achieve full PNEC-compliant supply chain by 2021
Short-term Goals:
  • Complete sustainability assessments of Category C suppliers by 2022
  • Complete sustainability assessments for Category B suppliers by 2024

Environmental Challenges

  • Some 2020 objectives will go unrealised
  • Climate change and AMR posing a growing threat
  • Drug shortages due to fragile supply chain and price competition
  • Increased public and governmental scrutiny on environmental impact
  • Increased stakeholder scrutiny on AMR from antibiotic pollution
Mitigation Strategies
  • Developing the next stage of our Sustainability Strategy (Roadmap for 2025 and beyond)
  • Working with customers, suppliers and other partners to drive industry awareness and action on critical sustainability issues
  • Engaging with stakeholders to raise awareness of supply chain vulnerability
  • Expanding supply footprint and ensuring product registrations to reach patients globally
  • Implementing the AMR Industry Alliance’s Common Antibiotic Manufacturing Framework
  • Achieving PNEC compliance for SSPs
  • Developing environmental KPIs for 2021-2025
  • Implementing corrective and preventive measures to address key findings after audits

Supply Chain Management

Supplier Audits: 73 audits in 2018 and 2019

Responsible Procurement
  • Supplier Code of Conduct
  • PSCI principles
  • Sustainability Assessment Tool (SAT)
  • Self-Assessment Questionnaire (SAQ)

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GRI

Certifications: ISO 14001 (except China)

UN Sustainable Development Goals

  • 3
  • 6
  • 12
  • 13

The report details how initiatives contribute to these goals.

Sustainable Products & Innovation

  • PureActives®

Awards & Recognition

  • 2018 GSK Environmental Sustainability Suppliers Award

Reporting Period: 2020-2021

Environmental Metrics

Carbon Intensity:18.75 tCO2/ton of product in 2021

ESG Focus Areas

  • Minimising environmental impact
  • Improving human health and social impact
  • Acting responsibly

Environmental Achievements

  • 14% carbon emission reduction (against 2015 baseline)
  • 10% solid waste reduction (against 2015 baseline)
  • 50% improvement in relative CO2 efficiency
  • 45% energy reduction
  • 25% water reduction
  • 100% PNEC compliant across the entire supply chain of oral antibiotics
  • Integrated sustainability assessment into project management and capital expenditure approval processes
  • Launched ESG Ambition 2021–2030

Social Achievements

  • Donated nearly 60,000 face masks and installed two oxygen plants in hospitals in India during COVID-19
  • Reached 100,000 people in 100 hospitals throughout China with an awareness campaign on AMR
  • Installed 280 solar-powered streetlights in four villages near Toansa plant
  • Introduced new Centrient Code of Conduct and Business Partner Code of Conduct
  • Introduced SpeakUp platform for reporting breaches of the Code of Conduct
  • Established Human Rights Committee
  • Renovated two schools in Toansa, India

Governance Achievements

  • Increased female representation on Executive Committee and Board of Directors
  • Introduced a refined purpose, vision and strategy for the company

Climate Goals & Targets

Long-term Goals:
  • Net zero emissions (target year not explicitly stated, but implied by 2030 goals)
Medium-term Goals:
  • 50% reduction in carbon emission intensity by 2030
  • 90% of waste repurposed by 2030
  • Source 50% renewable electricity by 2030
  • 5% reduction in water consumption intensity by 2030
  • Sites and suppliers compliant with AMR IA Common Manufacturing Framework and PNEC target values by 2030
  • R&D projects pass Sustainability assessment (2025)
  • Increasing access of our life-saving antibiotics to 2 billion patients by 2030
  • 50,000+ lives touched by Centrient global community programme annually by 2030
  • 75% of top suppliers meet sustainability standards (2025)
Short-term Goals:
  • 35% reduction in carbon emission intensity by 2025
  • High level of employee engagement - in top 10% for our industry (2025)
  • 50% gender balance in senior management roles (2025)
  • Certified human and labour rights compliance in our operations (2024)
  • Several diverse members at Board level (2025)
  • 100% of eligible employees committed to Code of Conduct (2024)

Environmental Challenges

  • COVID-19 impact on operations and supply chains
  • Drug shortages due to fragile supply chain
  • Antimicrobial resistance (AMR)
  • Reducing scope 3 emissions
Mitigation Strategies
  • Established local and global task forces to address COVID-19 challenges
  • Implemented multi-supplier strategy to secure supply chain
  • Developed comprehensive approach to eliminate AMR from wastewater treatment operations
  • Developed an internal AMR survey for assessing AMR risks in the antibiotic supply chain
  • Working on aligning climate targets with science-based targets (SBTs)

Supply Chain Management

Supplier Audits: 13 PSCI sustainability audits conducted in 2021, with 5 more planned for 2022. 73 suppliers passed ESG assessments.

Responsible Procurement
  • Business Partner Code of Conduct
  • Sustainability self-assessment questionnaire (SAQ)
  • PSCI principles
  • AMR survey

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: GRI Standards: Core option

Certifications: ISO 14001

UN Sustainable Development Goals

  • 3
  • 6
  • 12
  • 13

Centrient links its material topics and efforts to SDGs 3 (Good Health and Well-being), 6 (Clean Water and Sanitation), 12 (Responsible Consumption and Production), and 13 (Climate Action).

Sustainable Products & Innovation

  • PureActives® range of APIs and FDFs

Awards & Recognition

  • EcoVadis Gold Sustainability rating (2020 and 2021)

Reporting Period: 2022-2023

Environmental Metrics

Total Carbon Emissions:Not disclosed
Scope 1 Emissions:Not disclosed
Scope 2 Emissions:Not disclosed
Scope 3 Emissions:Not disclosed
Renewable Energy Share:25%
Total Energy Consumption:Not disclosed
Water Consumption:Not disclosed
Waste Generated:Not disclosed
Carbon Intensity:18.30 tCO2e/ton of product (2023)

ESG Focus Areas

  • Antimicrobial resistance
  • Water and environment
  • Improving access
  • Science and Innovation
  • Climate and energy
  • Waste management
  • Responsible procurement
  • Human capital development
  • Human rights
  • Patient safety
  • Community impact

Environmental Achievements

  • 5% carbon emissions reduction compared to 2015 baseline
  • 10% energy intensity reduction compared to 2021 baseline
  • 25% electricity sourced from renewable sources
  • 97% of waste repurposed compared to 2015 baseline
  • 10% water consumption reduction compared to 2021 baseline
  • 100% compliance with PNEC limits
  • Santa Perpetua site (Spain) certified under AMR Industry Alliance scheme

Social Achievements

  • Established a Mobile Healthcare Unit in Toansa, India, benefitting more than 1,200 people in 2023
  • Reached 2,500 people impacted by the 2023 Toansa flooding by distributing essential medicines and hygiene kits
  • Impacted more than 45,000 lives around the world through CSR programme
  • 97% of eligible employees completed Code of Conduct certification (2023)
  • Completed Human Rights Impact assessment
  • Developed and established a Sustainable Sourcing Policy
  • Improved gender balance at senior level, with 30% of senior management roles held by women
  • Launched a Centrient Community Action strategy and framework
  • Facilitated 1.5 billion patient treatments globally (2023)

Governance Achievements

  • Maintained Gold rating for EcoVadis Supplier Assessment in 2022 and 2023
  • Completed the Human Rights Impact assessment
  • Developed and established a Sustainable Sourcing Policy

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • 50% reduction in carbon emission intensity by 2030
  • 90% of waste repurposed by 2030
  • 50% renewable electricity by 2030
  • Maximise water recycling and look for options to reduce groundwater use by 2030
  • Sites and suppliers compliant with AMR IA Common Manufacturing Framework and PNEC targets by 2030
  • Increasing access of life-saving antibiotics to 2 billion patients by 2030
  • 50,000+ lives touched by Centrient’s global community programme annually by 2030
Short-term Goals:
  • 35% reduction in carbon emission intensity by 2025
  • 5% reduction in water consumption intensity by 2025
  • R&D projects pass Sustainability assessment by 2025
  • High level of employee engagement - in top 10% for our industry by 2025
  • 50% gender balance in senior management roles by 2025
  • 75% of top suppliers meet sustainability standards by 2025

Environmental Challenges

  • Supply chain disruptions
  • Global shortages of essential medicines
  • Growing demand for medicines
  • Antimicrobial resistance (AMR)
Mitigation Strategies
  • Multi-supplier strategy to avoid dependence on single suppliers
  • Backward-integrated production for better supply chain control
  • Capacity increase projects at Toansa (India), Yushu (China), and Ramos Arizpe (Mexico)
  • Sustainable Antibiotics programme to reduce antibiotic emission and prevent AMR
  • 100% compliance with PNEC target values for all wastewater streams
  • Collaboration with AMR Industry Alliance and BSI for AMR certification

Supply Chain Management

Supplier Audits: 10 key suppliers assessed in 2023; 6 PSCI sustainability audits conducted in 2022-2023

Responsible Procurement
  • Business Partner Code of Conduct (BPCoC)
  • Sustainability self-assessment questionnaire (SAQ)
  • PSCI principles
  • AMR survey

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Development of energy-efficient products

Reporting Standards

Frameworks Used: GRI Core Option, UN Sustainable Development Goals (SDGs)

Certifications: ISO 14001

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

  • 3
  • 6
  • 12
  • 13

Centrient's initiatives contribute to these goals through improving access to medicines, responsible water and waste management, sustainable energy use, and climate action.

Sustainable Products & Innovation

  • PureActives® range of enzymatically produced antibiotics

Awards & Recognition

  • Gold Sustainability Rating from EcoVadis (2022 and 2023)

Reporting Period: 2023

Environmental Metrics

Renewable Energy Share:25% (2023, compared to 2015 baseline)

ESG Focus Areas

  • Environmental
  • Social
  • Governance
  • Antimicrobial Resistance (AMR)

Environmental Achievements

  • 97% of waste repurposed (compared to 2021 baseline)
  • 10% water consumption reduction (compared to 2021 baseline)
  • 25% electricity sourced from renewable sources (compared to 2015 baseline)
  • 46.2% absolute reduction in scope 1 and 2 greenhouse gas emissions by 2031 (target)
  • 27.5% absolute reduction in scope 3 greenhouse gas emissions by 2031 (target)

Social Achievements

  • Facilitated 1.5 billion patient treatments globally (2023)
  • 97% of all eligible employees completed Code of Conduct certification (2023)
  • Launched a Centrient Community Action strategy and framework
  • Established a Mobile Healthcare Unit in Toansa, India, benefitting more than 1,200 people in 2023
  • Impacted more than 45,000 lives around the world through CSR programs and activities
  • Reached 2,500 people impacted by the 2023 Toansa flooding by distributing essential medicines and hygiene kits

Governance Achievements

  • Maintained 100% compliance with PNEC limits
  • Certified Spain site under new AMR IA scheme
  • Introduced shadow carbon pricing evaluation for key investments
  • Climate targets validated by the Science Based Targets initiative (SBTi)
  • Reported data to the Carbon Disclosure Project for the first time in July 2023
  • Developed and established a Sustainable Sourcing Policy
  • Maintained EcoVadis Gold rating in 2022 and 2023

Climate Goals & Targets

Long-term Goals:
  • 46.2% absolute reduction in scope 1 and 2 GHG emissions by 2031
  • 27.5% absolute reduction in scope 3 GHG emissions by 2031
  • 50,000+ lives touched by Centrient global community programme annually by 2030
Medium-term Goals:
  • Source 50% renewable electricity by 2030
  • Increasing access of our lifesaving antibiotics to 2 billion patients by 2030
  • 90% of waste repurposed and landfill only if no viable alternative available by 2030
Short-term Goals:
  • 5% reduction in water consumption intensity by 2030
  • R&D projects pass Sustainability assessment (2025)
  • Sites and suppliers compliant with AMR IA Common Manufacturing Framework and Predicted No-Effect Concentration targets
  • High level of employee engagement - in top 10% for our industry (2025)
  • 50% gender balance in senior management roles (2025)
  • 100% of eligible employees committed to Code of Conduct (2024)
  • Certified human and labour rights compliance in our operations (2024)
  • 75% of top suppliers meet sustainability standards (2025)

Supply Chain Management

Responsible Procurement
  • Sustainable Sourcing Policy

Climate-Related Risks & Opportunities

Sustainable Products & Innovation

  • PureActives (enzymatic platform)